Purpose or Objective: To evaluate the feasibility and clinical utility of integrating sequential PSMA-PET imaging into an offline–online adaptive workflow for response-based dominant intraprostatic lesion (DIL)-boosting high-risk prostate cancer treated with stereotactic ablative radiotherapy (SABR). This evidence concerns the gene FOLH1 and prostate carcinoma.